---
title: Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A
date: '2024-07-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39018533/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240718181716&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: In children with severe hemophilia A, once-weekly prophylaxis
  with efanesoctocog alfa provided high sustained factor VIII activity in the normal
  to near-normal range (>40 IU per deciliter) for 3 days and more than 10 IU per deciliter
  for almost 7 days after administration, leading to effective bleeding prevention.
  Efanesoctocog alfa was associated with mainly nonserious adverse events. (Funded
  by Sanofi and Sobi; XTEND-Kids ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: In children with severe hemophilia A, once-weekly prophylaxis with efanesoctocog alfa provided high sustained factor VIII activity in the normal to near-normal range (>40 IU per deciliter) for 3 days and more than 10 IU per deciliter for almost 7 days after administration, leading to effective bleeding prevention. Efanesoctocog alfa was associated with mainly nonserious adverse events. (Funded by Sanofi and Sobi; XTEND-Kids ClinicalTrials.gov number, ...